Clinical trial · Interventional
Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
NCT02724358CI-TRIAL-00021554completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Notch1 | — | UNRESOLVED | — |
| Rg3 | — | UNRESOLVED | — |
| TACE | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| protective therapy | Procedure | — | UNRESOLVED |
| Rg3 | Drug | — | UNRESOLVED |
| TACE | Procedure | — | UNRESOLVED |
| TACE + Rg3 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- TACE
- description
- iodized oil (5ml) + Pirarubicin (20mg)
- interventionNames
- Procedure: TACE
- type
- EXPERIMENTAL
- label
- Rg3
- description
- 20mg, BID, maintained though Month 12
- interventionNames
- Drug: Rg3
- type
- EXPERIMENTAL
- label
- TACE + Rg3
- description
- the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed hepatocellular carcinoma. 2. High expression of Notch1 in tumor tissues. Exclusion Criteria: no pathological evidence of HCC
References
Publications (0)
Data not yet available
No reference posted for this study.